8-K: VolitionRx Enters $7.5 Million Capital On Demand Sales Agreement with JonesTrading

VolitionRx Limited has entered into a sales agreement with JonesTrading Institutional Services LLC to offer and sell up to $7.5 million of its common stock through an 'at the market' offering.

Summary

• VolitionRx Limited has entered into a Capital On Demand Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to offer and sell up to $7.5 million of its common stock.
• The shares will be sold through an 'at the market' offering, which includes sales directly on NYSE American or in privately negotiated transactions.
• The company is not obligated to sell any shares under the agreement.
• Net proceeds from the offering, if any, will be used for research and product development, clinical studies, product commercialization, working capital, and potential strategic acquisitions.
• JonesTrading will receive a commission of up to 3.0% of the gross proceeds from each sale of shares.
• The Sales Agreement replaces the prior Equity Distribution Agreement with Jefferies LLC, dated May 20, 2022, which related to an at the market offering of shares of Common Stock having an aggregate offering price of up to $25.0 million.
• VolitionRx terminated the Prior ATM Agreement with Jefferies, effective April 20, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the capital raise provides financial flexibility, it also introduces potential dilution for existing shareholders. The company's intended use of proceeds is positive, but the success of those endeavors is uncertain.

Positives

• The Capital On Demand Sales Agreement provides VolitionRx with financial flexibility to raise capital as needed.
• The proceeds from the offering can be used to fund research and development, clinical studies, and commercialization efforts.
• The agreement allows for sales through multiple channels, including direct sales on NYSE American and privately negotiated transactions.

Negatives

• The company is not obligated to sell any shares, so there is no guarantee that the full $7.5 million will be raised.
• Existing shareholders may experience dilution if the company sells a significant number of shares.
• The company will incur commissions of up to 3.0% on any shares sold, reducing the net proceeds received.

Risks

• The company's stock price could be negatively impacted by the offering of new shares.
• There is no guarantee that the company will be able to successfully deploy the proceeds from the offering.
• The company's research and development efforts may not be successful, and its products may not achieve commercial success.

Future Outlook

The company intends to use the net proceeds from the offering, if any, for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.

Industry Context

At-the-market offerings are a common way for companies, particularly in the biotech and pharmaceutical industries, to raise capital without the need for a traditional underwritten offering. This provides flexibility in accessing funds based on market conditions and the company's specific needs.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as Geron Corporation and Agenus Inc., have utilized ATM offerings to fund clinical trials and research initiatives.
• The commission rate of up to 3.0% is within the typical range for ATM offerings, which generally fall between 1% and 5% depending on the size and complexity of the offering.
• The size of the offering, $7.5 million, is relatively small compared to some larger biotech companies, but is appropriate for a company of VolitionRx's size and stage of development.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• Employees may benefit from increased funding for research and development.
• Customers may benefit from the commercialization of new products.
• The company's financial position may be strengthened by the capital raise.

Next Steps

• VolitionRx may issue Placement Notices to JonesTrading to initiate sales of common stock.
• JonesTrading will attempt to sell the shares in accordance with the terms of the Sales Agreement.
• The company will file prospectus supplements with the SEC to report the amount of shares sold, net proceeds, and compensation paid to JonesTrading.

Key Dates

Keywords

Capital On Demand, Sales Agreement, VolitionRx, JonesTrading, Common Stock, At the market offering, Equity financing, Share issuance